Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 6 of 14

9. Precigen Inc (NASDAQ:PGEN)

Number of Hedge Fund Holders In Q4 2024: 10

Precigen Inc (NASDAQ:PGEN) is a company that makes gene and cell therapies with precision technology. It targets diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

The stock is up significantly so far in 2025 as the FDA granted Priority Review to the company’s Biologics License Application (BLA) for PRGN-2012.

This is an investigational AdenoVerse gene therapy that could treat adults with recurrent respiratory papillomatosis (RRP). This announcement came on February 25, 2025, with the FDA setting a Prescription Drug User Fee Act (PDUFA) target action date of August 27, 2025.

The consensus price target of $7 implies 300% upside.

PGEN is up 55.36% year-to-date.

Page 6 of 14